Stock VICORE PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Vicore Pharma Holding AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
Other stock markets
- SEK - Intraday chart for Vicore Pharma Holding AB
07/05 Vicore Pharma Holding AB Announces Board Appointments CI
03/05 Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 52M 4.85M 404M Sales 2025 * 393M 36.7M 3.06B Capitalization 2.2B 205M 17.1B
Net income 2024 * -236M -22.03M -1.83B Net income 2025 * -173M -16.15M -1.34B EV / Sales 2024 * 36.5 x
Net cash position 2024 * 304M 28.42M 2.37B Net cash position 2025 * 210M 19.62M 1.63B EV / Sales 2025 * 5.06 x
P/E ratio 2024 *
-12.1 x
P/E ratio 2025 *
-8.38 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.02%
More Fundamentals * Assessed data

Latest news about Vicore Pharma Holding AB

Vicore Pharma Holding AB Announces Board Appointments CI
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates CI
Vicore Pharma Holding AB Appoints Bertil Lindmark as Chief Medical Officer CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vicore Pharma Holding AB Announces the Nomination Committee for the 2024 Annual General Meeting CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106 CI
Certain Shares of Vicore Pharma Holding AB are subject to a Lock-Up Agreement Ending on 11-SEP-2023. CI
Vicore Pharma's New CEO to Formally Take Office MT
More news

Latest transcript on Vicore Pharma Holding AB

Logo Vicore Pharma Holding AB
Vicore Pharma Holding AB - Special Call
More transcripts

Press releases Vicore Pharma Holding AB

Vicore Expands and Strengthens its Board of Directors AQ
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ) AQ
Interim report January-March 2024 AQ
Vicore to Present at Upcoming April 2024 Investor Conferences AQ
Vicore to Present at Upcoming Investor Conferences AQ
More press releases

Managers and Directors - Vicore Pharma Holding AB

Managers TitleAgeSince
Ahmed Mousa CEO
 Chief Executive Officer 40 09/23/09
Hans Jeppsson DFI
 Director of Finance/CFO - 01/17/01
Elin Rosendahl CTO
 Chief Tech/Sci/R&D Officer - 16/20/16
Members of the board TitleAgeSince
Jacob Uno Stanley Gunterberg BRD
 Director/Board Member 57 01/18/01
Johannes G. C. P. Schikan CHM
 Chairman 66 01/18/01
Michael Buschle BRD
 Director/Board Member 64 01/23/01
More insiders

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Sector
Biotechnology & Medical Research
Calendar
19/05/2024 - American Thoracic Society Conference
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-1.05% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.84B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VICO Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW